The record.
Published research behind Flore Clinical, and the translational-science record of the team that built it.
Published research
Authored by the scientific team at Sun Genomics, Inc. (now Flore Clinical) in mSystems, the American Society for Microbiology's open-access journal.
Precision synbiotics in autism spectrum disorder
Phan J, Calvo DC, Nair D, Jain S, Montagne T, Dietsche S, Blanchard K, Treadwell S, Adams J, Krajmalnik-Brown R.
PubMed 38661344 · doi:10.1128/msystems.00503-24
Collaboration with Arizona State University's Biodesign Center for Health Through Microbiomes.
Gut microbiome alterations in irritable bowel syndrome
Phan J, Nair D, Jain S, Montagne T, Flores DV, Nguyen A, Dietsche S, Gombar S, Cotter P.
PubMed 34726487 · doi:10.1128/mSystems.01215-21
Collaboration with Paul Cotter (APC Microbiome Ireland / Teagasc Food Research Centre).
Real-world GI resolution curve
Beyond the published trials, Flore tracks patient-reported symptoms within its own paired real-world cohort as each formulation is iterated against repeat sequencing. These are real-world, observational signals, not a controlled trial — and because there is no control arm, Flore does not publish condition-level efficacy percentages.
Patients report improvement as formulas iterate
In the paired GI cohort (n=651), many patients report that their symptoms improve across successive formulation cycles, and repeat sequencing can show measurable microbiome change over time. Because this is observational data with no control arm, these are directional real-world signals — hypothesis-generating, not proof of efficacy — so we describe the trajectory qualitatively rather than publishing condition-level resolution percentages.
| Follow-up interval | Patient-reported trend |
|---|---|
| First interval (<6 months) | Many patients report early symptom improvement |
| Later in the course (~20 months) | Improvement is often sustained or greater as formulas iterate |
Signals are drawn from a paired real-world cohort tracked across ~6.6-month median intervals and followed longitudinally out to 20 months. Because the dataset has no control arm, Flore does not publish condition-level efficacy percentages; these patient-reported observations are hypothesis-generating and do not establish efficacy. Real-world evidence, not a controlled trial. No statement here is a disease claim.
Founder's translational-science record
Peer-reviewed publications by Craig J. Rouskey, MSc (ORCID 0009-0001-6794-5346) preceding the microbiome focus.
Durable adoptive immunotherapy for leukemia
Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM.
PubMed 23188506 · doi:10.1158/0008-5472.CAN-12-2179
Performed at Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, under Ryan M. Teague. Collaborating co-author: Philip D. Greenberg (Fred Hutchinson Cancer Center).
Recombinant Peru-15 cholera toxin B vaccine against enterotoxigenic E. coli
Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP.
PubMed 18045752 · doi:10.1016/j.vaccine.2007.09.074
AVant Immunotherapeutics, Needham, MA.
Clinical background
Evidence-aligned clinical reviews from the Flore Clinical Journal.
Probiotics in Clinical Practice: Evidence-Based Applications
Dysbiosis and Disease: Understanding the Microbial Imbalance
C. difficile: Prevention and Microbiome-Based Treatment